Edwards Lifesciences Corp (EW)vsRLX Technology Inc (RLX)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
RLX
RLX Technology Inc
$2.21
+2.31%
CONSUMER DEFENSIVE · Cap: $2.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 68% more annual revenue ($6.07B vs $3.62B). RLX leads profitability with a 25.5% profit margin vs 17.7%. RLX trades at a lower P/E of 21.6x. RLX earns a higher WallStSmart Score of 68/100 (B-).
EW
Buy55
out of 100
Grade: C
RLX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Margin of Safety
+47.9%
Fair Value
$4.68
Current Price
$2.21
$2.47 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Revenue surging 46.8% year-over-year
Earnings expanding 81.9% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
ROE of 5.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : RLX
The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : RLX
The primary concerns for RLX are Return on Equity.
Key Dynamics to Monitor
EW profiles as a mature stock while RLX is a growth play — different risk/reward profiles.
RLX carries more volatility with a beta of 1.23 — expect wider price swings.
RLX is growing revenue faster at 46.8% — sustainability is the question.
RLX generates stronger free cash flow (358M), providing more financial flexibility.
Bottom Line
RLX scores higher overall (68/100 vs 55/100), backed by strong 25.5% margins and 46.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →RLX Technology Inc
CONSUMER DEFENSIVE · TOBACCO · China
RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?